In a phase IIa trial, mTORC1 inhibitors improved vaccine response and reduced infections in older people. ConfidenceEstablished Level of evidence●●●●●○ Randomized clinical trial Observed inHuman MissionMap of aging (12 hallmarks) ConceptsChronic inflammationmTOR (mTORC1)Deregulated nutrient sensing